Meeting Archives
Chemotherapy Foundation Symposium XXIV
November 7-10, 2007
Marriott Marquis Hotel , New York , NY
Innovative Cancer Therapy for Tomorrow
Breast Cancer
| Norman Wolmark, MD | Breast Cancer Prevention and The NSABP Clinical Trials: Keynote Address | View Presentation |
| James F.Holland, MD | The Human Mammary Tumor Virus: Fact, Not Fiction: EMG Lecture | View Presentation |
| Howard A.Burris, MD | Next Generation Herceptin - The Trastuzumab DM-1 Cytotoxic Antibody | View Presentation |
| Clifford A.Hudis, MD | Anti-HER2 Therapy: Beyond Trastuzumab | View Presentation |
| Howard A.Burris, MD | Clinical Update on 2nd Generation Epothilone KOS-1584 | View Presentation |
| Massimo Cristofanilli, MDFACP | Lapatinib/ Paclitaxel for Inflammatory Breast Cancer | View Presentation |
| Helen K.Chew, MD | EGFR Inhibition with Lapatinib in Combination with Vinorelbine: A Phase I Study | View Presentation |
| Larry Norton, MD | Rational Design of Dose and Schedule of Anticancer Agents | View Presentation |
| William J.Gradishar, MD | Clinical Activity of Capecitabine Plus Bevacizumab in Metastatic Disease | View Presentation |
| Deepali Sachdev, MDPh.D | The Type I Insulin-Like Growth Factor Receptor (IGF-1R) as a Target for Cancer Therapy | View Presentation |
| Allan Lipton, MD | Serum HER-2/ NEU as a Predictor of Response to Her-2/NEU Targeted Therapies | View Presentation |
| Joseph Sparano, MD | Clinical Application of Molecular Profiling | View Presentation |
| Peter Ravdin, MD | Recent Changes in Incidence and Mortality in The US | View Presentation |
| Nancy Lin, MD | Systemic Therapy for Breast Cancer Brain Metastases | View Presentation |
| Hope Rugo & Andrew Seidman D.Seidman, MD | Oncotype DX: Impact on Therapeutic Decisions: Recent Data and Case Studies | View Presentation |
GI Cancers
| Axel Grothey, MD | Does Bevacizumab Work Equally Well with All Chemotherapy Drugs? Conflicting Views | View Presentation |
| Leonard B.Saltz, MD | Does Bevacizumab Work Equally Well with All Chemotherapy Drugs? Conflicting Views | View Presentation |
| Edward Chu, MD | Integration of Biological Agents for Advanced Colorectal Cancer | View Presentation |
| Howard S.Hochster, MD | Expanding Role of Cetuximab in the First and Second-Line Therapy of Colorectal Cancer | View Presentation |
| Mace Rothenberg, MD | Clinical Trials of Small Molecule Inhibitors in CRC | View Presentation |
| David M.Goldenberg, MD | Radioimmunotherapy in Post-Salvage Resection of Colorectal Liver Metastases | View Presentation |
| Lisa A.Kachnic, MD | The Integration of Novel Agents in Chemoradiation for Rectal Cancer | View Presentation |
| Wasaburo Koizumi, MD | New Standard Therapy for Gastric Cancer | View Presentation |
| David H.Ilson, MD | Advances in The Treatment of Esophagogastric Cancer | View Presentation |
| Jorge Gallardo, MD | Multimodality Treatment of Gall Bladder Cancer | View Presentation |
| Howard A.Burris, MD | RAV12 for GI Cancers: A Novel Cytotoxic Monoclonal Antibody | View Presentation |
| Jordan Berlin, MD | Panitumumab: Different Antibody or the Same Thing, Different Results? | View Presentation |
| Robert J.Jones, Ph.DMBChB | Xaliproden: Preventing Oxaliplatin Neurotoxicity | View Presentation |
| Daniel Labow, MD | Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Gastric Cancer | View Presentation |
| Paulo M.Hoff, MDFACP | Continuum of Care in Colorectal Cancer | View Presentation |
| Mace Rothenberg, MD | Continuum of Care in Colorectal Cancer | View Presentation |
| Ghassan K.Abou, MD | Advances in Systemic Therapy | View Presentation |
| Andrew X.Zhu, MDPh.D | Emerging Molecular Targeted Therapies | View Presentation |
Gliomas
| Mark R.Gilbert, MD | Bevacizumab for Malignant Gliomas: Results and Future Directions | View Presentation |
Gynelogical Cancers
| Franco M.Muggia, MD | Pegylated Liposomal Doxorubicin: Dose-Scheduling, Combinations and Maintenance | View Presentation |
| Tamar Safra, MD | Is Hereditary Ovarian Cancer More Responsive to Chemotherapy? Reviewing the Evidence | View Presentation |
| Carol Aghajanian, MD | New Agents in Ovarian Cancer | View Presentation |
| Maurie Markman, MD | The Role of Intraperitoneal Drug Delivery in the Management of Ovarian Cancer | View Presentation |
| Keiichi Fujiwara, MD | IP Carboplatin-Based Chemotherapy for Ovarian Cancer | View Presentation |
| Robert Bast, MD | Biomarkers for Ovarian Cancer | View Presentation |
| Thomas J.Herzog, MD | The GOG Trials | View Presentation |
| William P.McGuire, MD | Overview of National and International Phase III Trials in Ovarian Cancer | View Presentation |
| Carol Krasner, MD | Trabectedin in Relapsed Advanced Ovarian Cancer | View Presentation |
| Bradley J.Monk, MDFACOG, FACS | Issues in Cervical Cancer | View Presentation |
| Tamar Safra, MD | Role of Topotecan in the Management of Cervical Carcinoma | View Presentation |
Head and Neck Cancers
| Ezra Cohen, MD | Emerging Systemic Therapies | View Presentation |
| Gregory T.Wolf, MD | Novel Immunotherapy | View Presentation |
Hematologic Malignancies
| Michael J.Mauro, MD | Overcoming Drug Resistance in CML: Three Generations of Tyrosine Kinase Inhibitors | View Presentation |
| Kanti R.Rai, MD | Risk-Adapted Therapeutic Options in CLL | View Presentation |
| Harry P.Erba, MD | New Options in Elderly Naïve and Relapsed AML | View Presentation |
| William Blum, MD | The Role of Epigenetic Therapy in AML | View Presentation |
| Guillermo Garcia, MD | Update on Treatment Options in MDS and AML | View Presentation |
| Gail J.Roboz, MD | Lenalidomide in MDS: Update on Non DEL 5Q Patients | View Presentation |
| Michael Wang, MD | Novel Therapies for Mantle Cell Lymphoma | View Presentation |
| James R.Berenson, MD | Bortezomib and SM-153 Lexidronam Combination Therapy in Mutiple Myeloma | View Presentation |
| John P.Leonard, MD | Rituximab Combinations in NHL | View Presentation |
| David Vesole, | Lenalidomide in Plasma Cell Dyscrasias | View Presentation |
| Frank J.Giles, MD | CP-4055, A Novel Nucleoside Analog | View Presentation |
| Myron Czuczman, MD | Update on Galiximab: Anti-CD80 Monoclonal Antibody | View Presentation |
| John A.Glaspy, MD | Management of Multiple Cytopenias Safety of ESA's in Oncology | View Presentation |
| James B Bussel, MD | Novel Approaches to Diagnosis and Management of Thrombocytopenia | View Presentation |
| Phillip Cohen, MD | Bendamustine and Rituximab in Indolent and Mantle Cell Lymphoma | View Presentation |
| Jonathan W.Friedberg, MD | Options: Non-Hodgkin's Lymphoma | View Presentation |
Late Breaking Developments
| Susan O'Brien, MD | Marqibo for the Treatment of Adult Lymphoblastic Leukemia | View Presentation |
| David Lawson, MD | Randomized Phase II Trial of Paclitaxel with or without STA 4783 in Metastatic Melanoma | View Presentation |
Lung Cancer
| Paul A.Bunn, MD | Biologic Selection Markers For EGFR TKIS | View Presentation |
| Chandra P.Belani, MD | NSCLC: VEGFR Targeted Agents Beyond Bevacizumab | View Presentation |
| Robert M.Jotte, MD | Amrubicin in SCLC | View Presentation |
| Mark A.Socinski, MD | Sunitinib in Lung Cancer | View Presentation |
| Nassar H.Hanna, MD | Non-Smokers: NSCLC | View Presentation |
| Avrum Spira, MD | Airway Gene Expression as a Novel Diagnostic Biomarker for Lung Cancer | View Presentation |
| Rogerio Lilenbaum, MD | Update on Elderly and PS 2 Patients with Advanced NSCLC | View Presentation |
Melanoma
| Svetomir N.Markovic, MD | Aerosolized GM-CSF | View Presentation |
| Ravi Amaravadi, MD | Temozolomide and Sorafenib for Patients with or without Brain Metastases: Phase II Results | View Presentation |
| Richard Royal, | Regional Treatment Strategies for Patients With Hepatic Metastases From Melanoma | View Presentation |
| Anna Pavlick, MD | Preliminary Results of Genasense, Temazolamide and Abraxane Combination in Advanced Melanoma | View Presentation |
Neuroendocrine
| Andrew S.Kennedy, MDFACRO | Radioembolization for Neuroendocrine Hepatic Metastases | View Presentation |
Pediatric Oncology
| Birte Wistinghausen, MD | Post Transplant Lymphoproliferative Disorder | View Presentation |
| John Gregory, MD | Recent Clinical Trials in Acute Promyelocytic Leukemia | View Presentation |
| Scott Howard, MD | Identifying Patients at Risk for Tumor LYSIS Syndrome | View Presentation |
| Glen Lew, MD | Treatment of Relapsed Acute Lymphoblastic Leukemia in Childhood | View Presentation |
| David A.Jacobsohn, MD | Hematopoietic Stem Cell Transplantation in Pediatric ALL | View Presentation |
| Stephen A.Sands, Psy.D | Psycho-Social Outcomes in Pediatric Oncology Patients | View Presentation |
| Sima Jeha, MD | Novel Strategies for Relapsed Childhood Leukemia | View Presentation |
Solid Tumors
| Allan Lipton, MD | Denosumab in Breast and Prostate Cancer | View Presentation |
| Roger B.Cohen, MD | Targeting Death Receptors with Agnostic Monoclonal Antibodies | View Presentation |
The 21st Century Cancer Revolution
| Charles Sawyers, MD | Targeted Therapies -The Next Wave | View Presentation |
| John J.Wright, MD | Emerging Targets in Development - A View from the NCI | View Presentation |
| Julio Aguirre, MD | Dormant Cancer Cells: The Root Cause? | View Presentation |
Uro-Oncology: Bladder Cancer
| Daniel Saltzstein, MD | Apaziquone - A New Agent for Adjuvant Therapy in Non-Invasive Bladder Cancer | View Presentation |
Uro-Oncology: Prostate
| Edith A.Perez, MD | Modulation Drug Resistance | View Presentation |
| Hope S.Rugo, MD | Management of Taxane Toxicity | View Presentation |
| A. Oliver Sartor, MD | Satraplatin Update | View Presentation |
| Michael A.Carducci, MD | GVAX in Prostate Cancer | View Presentation |
| Anna C.Ferrari, MD | New Agents and Combinations | View Presentation |
| Daniel P.Petrylak, MD | Advances in Second Line Therapy For Hormone Refractory Prostate Cancer | View Presentation |
Uro-Oncology: Renal
| Janice P.Dutcher, MD | Sunitinib in Renal Cell Cancer: Expanded Access | View Presentation |
